Many diseases affect pre-mRNA splicing, and alternative splicing is a major source of proteome diversity and an important mechanism for modulating gene expression. The ability to regulate a specific splicing event is therefore desirable; for example, to understand splicing-associated pathologies. We have developed methods based on modified U7 snRNAs, which allow us to induce efficient skipping or inclusion of selected exons. Here, we have adapted these U7 tools to a regulatable system that relies on a doxycyclinesensitive version of the Krü ppel-associated box (KRAB)/ KAP1 transcriptional silencing. Co-transduction of target cells with two lentiviral vectors, one carrying the KRAB protein and the other the regulatable U7 cassette, allows a tight regulation of the modified U7 snRNA. No leakage is observed in the repressed state, whereas full induction can be obtained with doxycycline in ng ml À1 concentrations. Only a few days are necessary for a full switch, and the induction/ repression can be repeated over several cycles without noticeable loss of control. Importantly, the U7 expression correlates with splicing correction, as shown for the skipping of an aberrant b-globin exon created by a thalassaemic mutation and the promotion of exon 7 inclusion in the human SMN2 gene, an important therapeutic target for spinal muscular atrophy.
Introduction
Recent evidence indicates that alternative pre-mRNA splicing is not just an intriguing peculiarity in the expression of certain genes, but a wide-spread regulatory phenomenon that drastically increases the diversity of the proteome. 1 In humans, approximately two-thirds of the 20 000-30 000 genes can be alternatively spliced to generate at least two (and sometimes many) different forms of mRNA, resulting in a coding potential of more than 100 000 different proteins. Splicing regulation is a complex process that is controlled by the interplay of multiple trans-acting factors with cis-acting elements found within the pre-mRNA. 2 Owing to its complexity, this process is highly vulnerable, and, as a consequence, more and more mutations causing hereditary diseases are found to affect alternative splicing decisions (reviewed in Cartegni et al. 3 ). On account of the great medical importance of alternative splicing, methods have been developed to modulate this process in a gene-and exon-specific way. The skipping of a particular exon or a switch between alternative 5 0 or 3 0 splice sites (ss) can be achieved by the use of RNAse H-resistant antisense oligonucleotides, which act by masking ss or other regulatory signals contributing to exon recognition (exonic or intronic splicing enhancers and silencers). 4 This approach has now entered the therapeutic era in the case of Duchenne muscular dystrophy. 5 Another way to achieve the same goal is to express, within the target cells, antisense RNAs that can modulate splicing in very much the same way. Ideal expression vehicles for this gene therapeutic approach are derivatives of small nuclear RNAs that form stable ribonucleoprotein particles in the nucleoplasmic compartment. Our group has developed such an antisense expression system relying on the use of a modified U7 snRNA (U7 Sm OPT) (reviewed in Asparuhova et al. 6 ). This system has been successfully used to induce exon skipping in a variety of genes and disorders including thalassaemic b-globin mutations, 7, 8 Duchenne muscular dystrophy [9] [10] [11] and human immunodeficiency virus type 1/acquired immune deficiency syndrome. 12, 13 More recently, we and others have shown that the U7 SmOPT tool can also be adapted to promote exon inclusion in the case of the human SMN2 gene, a potential therapeutic target for spinal muscular atrophy (SMA). 14, 15 Although oligonucleotides, such as drugs, can be applied and withdrawn to obtain a temporal control over therapeutic and possible side effects, a gene therapeutic approach is theoretically permanent and can only be controlled if the gene expression cassette includes a regulatory mechanism for its induction and/or repres-sion. A system that allows one to control the modulation of a splicing event could also be an important experimental tool for obtaining insights into the physiological relevance of differently spliced mRNAs and their encoded proteins or to study the optimal time frame for a therapeutic intervention (for example, for a disease occurring very early in ontogenesis). Regulatable systems are now often used for protein-coding genes. However, most U snRNAs are transcribed from a particular type of constitutively active RNA polymerase II promoters (except for U6 snRNA, which is transcribed by RNA polymerase III) for which regulatory systems have so far not been developed. 16 Transcription, 3 0 -end formation and maturation of the snRNA and its assembly into snRNP particles are interdependent processes, [17] [18] [19] such that a U snRNA promoter can not simply be exchanged by a regulated mRNA promoter. Here we have adapted a system originally designed for the doxycycline-regulated expression of short hairpin RNAs. 20 As a result, we obtained a tight regulation of modified U7 snRNA genes. This versatile system has allowed us to study dose requirements of U7-based exon inclusion and exclusion. It should be adaptable to in vivo situations, for example, in transgenic animals.
Results

Development of a regulatable U7 expression system
On account of the particularities of U snRNA promoters mentioned in the Introduction, we could not use the basic approach for transcriptional regulation relying on a minimal promoter combined with a drug-activated or drug-inhibited transactivator 21 to control the expression of an engineered U7 snRNA. We therefore decided to take advantage of a recently developed system in which regulated gene silencing is indirectly achieved by the Krü ppel-associated box (KRAB) protein domain fused to the tTR repressor. 20 Depending on the presence or absence of tetracycline (or its doxycycline analog), this fusion protein conditionally binds to tet operator (tetO) sequences and is consequently able to silence gene expression from pol-I, -II and -III promoters within a range of several kilobases (Figure 1b) , presumably by triggering heterochromatin formation. 20, 22 To investigate whether this silencing can be applied to the (murine) U7 snRNA promoter, we inserted one of our modified U7 snRNA expression cassettes into the pLV-T plasmid. The latter is a second-generation SIN (SelfINactivating) lentiviral vector carrying seven copies of a tetO sequence in place of the deleted transcriptional regulatory elements of the 3 0 -LTR. 20 The U7 expression cassette was inserted upstream of the elongation factor 1a (EF1-a) promoter that drives green fluorescent protein (GFP) expression, in sense orientation with respect to the GFP coding sequence (Figure 1a) . The modified U7 snRNA that we initially tested was U7-ESE-B (Figure 1c ), which we have demonstrated earlier to enhance very efficiently the inclusion of the exon 7 in the human SMN2 gene. Enhancing the inclusion of this exon is considered as an attractive therapeutic strategy for SMA. 14 As an indirect measurement of U7 snRNA expression, we analysed exon 7 inclusion in HeLa cells stably expressing an SMN2-luciferase reporter gene. 23 When these HS2 cells were transduced with pLV-T carrying the U7-ESE-B cassette, they showed a strong GFP fluorescence correlating with the expected increase in exon 7 inclusion of the SMN2 reporter gene, from a basal 13 ± 3 to 75 ± 7% (Figures 1d and e) . These cells were subsequently transduced with a second lentiviral vector encoding the tTR-KRAB regulatory protein and a dsRed reporter gene and cultured either in the absence or in the presence of doxycycline. We evaluated by quantitative real-time PCR that these cells contain approximately 15 copies of the U7 vector and 10 copies of the tTR-KRAB vector (data not shown). GFP fluorescence analysis first confirmed that, as expected, this system allows a tight regulation of EF1-a, the pol-II promoter driving GFP expression (Figure 1d) . We also obtained a nearly perfect regulation of the splicing correction with a repressed state showing low leakiness with 17±3% exon 7 inclusion, a level close to that seen in non-corrected cells, and an induced level of 77±5%, which is equivalent to what is observed in the absence of the tTR-KRAB regulator (Figure 1e ). Note that the induction was sensitive to very low amounts of doxycycline (see below) and we had to use tetracyclinefree foetal calf serum to obtain a full repression. All the experiments described in this study were therefore performed with tetracycline-free foetal calf serum. As the analysis of SMN2 splicing correction is an indirect read-out of U7-ESE-B snRNA expression, we analysed most of the RNA samples from this study by a primer extension assay, allowing a quantitative comparison of U7-ESE-B and endogenous U2 snRNAs. An example of such an assay comprising samples used for the Figures 1 and 2 of this paper is shown in Supplementary Figure 1 online. It shows that U7-ESE-B expression levels of the cells transduced only by pLV-T carrying the U7-ESE-B cassette and of the doubly transduced cells in the presence of doxycycline are very similar. In contrast, the doubly transduced cells contain no detectable U7-ESE-B snRNA in the absence of doxycycline.
We also tested other configurations in which the U7 cassette was inserted in reverse orientation (with regard to the GFP coding sequence) upstream of the EF1-a promoter or in the 3 0 -SIN-LTR so that it is duplicated in the integrated proviral vector (both orientations tested). Although these constructs also responded to doxycycline regulation, they showed a reduced splicing correction (data not shown) so that we concentrated on the cloning position and orientation depicted in Figure 1a .
Characterization of the regulation system
We then investigated whether this regulation was reversible and stable over time. The doubly transduced HS2 cells described above were kept in culture in the absence or presence of doxycycline and then shifted back and forth between the two conditions several times over a period of 35 days. As shown in Figure 2 , the splicing correction could be repeatedly shifted from a repressed to an induced state and vice versa, without major loss of regulation (no leakiness, maximum level reached). We also directly assessed the expression of the U7-ESE-B snRNA by primer extension (dashed lines and Supplementary Figure 1 online). These data correlated well with the analyses of splicing correction by showing no detectable U7 snRNA in the repressed state and a relatively stable level (over multiple shifts) in the induced state.
Given the basal level of splicing correction observed when normal (not tetracycline-free) foetal calf serum was used (data not shown), we suspected that the induction would occur at very low levels of doxycycline. A doseresponse experiment indeed showed that full U7 expression and the corresponding maximal splicing correction was reached with a doxycycline concentration as low as 6 ng ml À1 of culture medium ( Figure 3 ). This impressively sensitive and sharp on/off behaviour of the system may also be responsible for the high standard deviation obtained for the two lowest doses (1 and 2 ng ml À1 in Figure 3 ), as the response would react very sensitively to minimal imprecisions in the doxycycline dilution.
We additionally tested the kinetics of induction and repression. Cells were first kept for 2 weeks in a stable doxycycline state (off or on) to ensure that the system was at equilibrium and then shifted for induction or repression, respectively. As observed earlier, there was a clear correlation between the U7-ESE-B level and the SMN2 exon 7 inclusion efficiency. About 48 h were necessary to reach a fully induced state (Figures 4a and b) . The repression kinetic was slower with full repression observed after more than 120 h (Figures 4c and d) .
Testing U7 snRNA regulation in an exon skipping model Having obtained this efficient regulation for the SMN2 exon 7 inclusion model, we asked whether the same regulatory system could be applied to another splicing correction strategy. To this end, we analysed the skipping of an aberrant b-globin exon created by certain b-thalassaemic mutations. These mutations create new 5 0 ss at positions 654, 705 or 745 of the second intron (IVS2) and activate a cryptic 3 0 ss at position 579/580, so that aberrant exons of various lengths are included in the mature mRNA for each of the mutations. In an earlier study, we have described several modified U7 snRNAs able to promote the skipping of these aberrant exons, the . (e) Representative agarose gel from an RT-PCR performed on RNA extracted from the cells described in the corresponding lanes. The FL (full-length) band represents the correctly spliced SMN2 mRNA including exon 7, whereas the Dex7 (delta exon 7) band corresponds to the truncated form that is predominantly found in SMA patients. The percentage of SMN2 exon 7 inclusion was evaluated by fragment analysis and calculated as described in Materials and methods. The level of exon 7 inclusion strongly correlates with the U7-ESE-B expression levels as measured by primer extension analysis (see Supplementary Figure 1 online and Figures 2-4) . GFP, green fluorescent protein; KRAB, Krü ppel-associated box; RT-PCR, reverse transcription PCR.
Doxycycline-regulated antisense U7 snRNA J Marquis et al most efficient being the construct U7-BP+5 0 654 that targets two different sequences in the pre-mRNA: the region of the putative branch points upstream of the cryptic 3 0 ss and the 5 0 ss created by the IVS2-654 mutation. 8 Here we used a newly designed, more efficient, U7 snRNA, named U7-Do3-Ex1, that targets a first sequence within the aberrant exon and a second sequence downstream of it. This construct is characterized in Supplementary Figure 2 online.
For the analysis, we used HeLa cells stably expressing the human b-globin gene with the IVS2-705 mutation. 24 These cells were sequentially transduced with the pLVT-U7 lentiviral vector (here carrying the U7-Do3-Ex1 construct) and the tTR-KRAB vector. The aberrant exon inclusion level was 100% in the absence of any treatment, whereas the single transduction with the U7-Do3-Ex1 vector led to a full splicing correction with 100% exon skipping ( Figure 5 ). Importantly, in the doubly transduced cells, no exon skipping was evident in the absence of doxycycline, whereas it was almost complete in the presence of the drug. Additional experiments showed that this regulatable exon skipping system was also fully reversible and had a similar sensitivity to very low doses of doxycycline, resulting in a very sharp on/off switch, similar to what we reported above for the SMN2 exon 7 inclusion model (data not shown). Although we have not studied the kinetics of this system extensively, preliminary data also suggest a very similar time course of induction and repression (data not shown).
Discussion
In this study, we have adapted the tTR-KRAB proteinbased regulation system developed for shRNAs 20 to tightly control the expression of modified U7 snRNAs. We documented this regulation with examples of exon skipping (b-globin aberrant exon; Figure 5 ) and exon inclusion (SMN2 exon 7; Figures 1-4) .
The regulation responds to very low doses of doxycycline ( Figure 3 ). In culture, this means that the cells have to be kept in tetracycline-free medium to reach a full repression. At least for the U7-ESE-B construct promoting SMN2 exon 7 inclusion, concentration dependence appears to be even slightly sharper for the splicing correction than for the U7 snRNA primer extension signals. This indicates that the used U7 construct is extremely efficient at inducing SMN2 exon 7 inclusion, which will be an important asset for gene therapy against SMA. However, this very sensitive and sharp induction behaviour also makes it virtually impossible to reach intermediary levels of splicing correction.
It is not known whether and how much the regulation may be affected by various copy number ratios between the U7/GFP and tTR-KRAB/dsRed vectors. One might expect an impact on the doxycycline dose dependence as well as the on/off kinetics. However, we expect the system to have at least a certain degree of tolerance, as both independently established regulatory examples (SMN2 exon 7 inclusion and aberrant b-thalassaemic exon skipping) display a very tight regulation. A convenient way of keeping this ratio constant might seem to be the 'all-in-one' regulation system in which both the expression cassette and the tTR-KRAB regulator are located in the same vector. 22 In addition, this could represent an interesting technical advantage, in particular if the system were to be used in transgenic animals, because a single transduction/transgenesis would be sufficient. However, owing to the intrinsic leakiness of this system and the high splicing correction efficiencyeven at a low dose-of our modified U7 snRNAs, this system showed a considerable splicing correction in the repressed state (data not shown). Figure 2 Reversibility of U7 snRNA induction and repression. HS2 cells transduced with the regulatable U7 and KRAB lentiviral vectors were submitted to three shifts between doxycyclinecontaining (1 mg ml À1 ) and doxycycline-free medium over a period of 35 days. The experiment was performed either by starting with cells equilibrated in the repressed state (without doxycycline) or in the induced state (with 1 mg ml À1 doxycycline). The percentage of SMN2 exon 7 inclusion (complete lines, y scale on the left-hand side) was evaluated by fragment analysis (FA) and calculated as described in Materials and methods. U7-ESE-B snRNA levels (dashed lines, y scale on the right-hand side) were determined by primer extension, normalized to U2 snRNA levels and then expressed as percentage of the highest value (induced state at the beginning of the experiment). Error bars represent the standard deviations calculated from three independent measurements. KRAB, Krü ppel-associated box. ; however, the highest levels are not shown). RNA was extracted 1 week after the beginning of the treatment. The percentage of SMN2 exon 7 inclusion and U7-ESE-B snRNA levels was determined and are represented as described in the legend of Figure 2 . Error bars represent the standard deviations calculated from two independent experiments, each carried out in duplicate. KRAB, Krü ppelassociated box.
Doxycycline-regulated antisense U7 snRNA J Marquis et al Such a system now opens the possibility to exogenously control splicing correction simply by applying doxycycline to the target cells. This could be applied to any exon inclusion/skipping control, provided that a suitable modified U7 snRNA is available. Given that alternative splicing concerns more than 60% of human genes 1 and that it is of major importance for the regulation of gene expression and proteome diversity, this tool represents an unprecedented opportunity to investigate the importance of individual splice variants on a cell's physiology, for instance related to apoptosis, 25 cancer 26 or specific cell functions, for example, in certain types of neurons. 27 The combined facts that this is a two-vector system, that its very sharp induction properties make it difficult to obtain intermediate expression levels (Figure 3 ) and that its properties in vivo have yet to be analysed do not presently make it an option for use in a human therapeutic setting. However, this system is ideally suited to decipher pathophysiological aspects of splicing-related diseases. 3 Taking the example of SMA (OMIM no. 253300), to what extent this is a developmental or degenerative disease is currently not clear.
At what time during ontogenesis are low levels of SMN particularly critical? Is there a point of no return after which a therapy (be it drug-or gene therapy-based) can no longer rescue the motoneurons from dying? Is this before or after birth and how does this time point differ among the different disease severities? Will the disease still develop if a correction of SMN2 splicing is discontinued after the first phases of post-natal life? Mouse models for SMA 28, 29 and transgenic mice expressing the tTR-KRAB regulator 30 are available. If these genotypes are combined with the regulatable U7-ESE-B cassette, many of the above questions could be addressed, simply by providing doxycycline through drinking water at different times during ontogenesis. Whether and how precisely this will be feasible will depend on the repression and induction kinetics observed in vivo (in our cell culture system B48 h and B120 h were necessary for full induction and repression, respectively) and on whether the silencing will not be irreversible in vivo. 30 Efficient transfer of the therapeutic U7-ESE-B cassette to motoneurons will need to be developed to approach a true somatic gene therapy for SMA. This may well À1 doxycycline. RNA was extracted at various time points and analysed for the percentage of SMN2 exon 7 inclusion by fragment analysis (a) and for U7-ESE-B snRNA levels by primer extension (b) as described in Materials and methods. The individual data points are derived from two independent experiments in which samples were harvested at different time points. The high variability in U7 levels determined by primer extension mainly stems from the use of different batches of labelled primers. The figure was generated with the Prism 4 software (Graphpad); the trend lines were generated by using a hyperbolic (one-site binding) model. (c and d) HS2 cells transduced with the regulatable U7 and KRAB lentiviral vectors, equilibrated in the induced state (1 mg ml À1 doxycycline), were shifted to medium lacking doxycycline. RNA was extracted at various time points and analysed by fragment analysis (c) and primer extension (d) as described above. All values were generated from a single experiment, and data points were connected by straight lines. KRAB, Krü ppel-associated box.
Doxycycline-regulated antisense U7 snRNA J Marquis et al require vectors other than lentiviral vectors (for example, adeno-associated virus vectors). Future research will have to show whether some aspects of the regulated system presented here can then be adapted to such a motoneuron transfer vector.
Materials and methods
Molecular cloning
The U7-ESE-B splicing correction cassette was described earlier. 14 The newly developed b-globin splicing correction cassette U7-Do3-Ex1 is described in Supplementary  Figure 2 online. The regulatable vector, pLV-T, is similar to pLV-TH 20 except that it does not carry the H1 promoter in its 3 0 -LTR. Both pLV-T and pLV-tTR-KRABRed 20 were kindly provided by Professor D Trono and collaborators (EPFL, Lausanne, Switzerland). Before ligation into the single ClaI site of pLV-T (upstream of the EF1-a promoter), U7 expression cassettes were amplified by PCR with primers U7-SfuI-Fw and U7-ClaI-Re and the products digested with SfuI and ClaI. The U7 gene was always in sense orientation with regard to the GFP gene. All constructs were verified by sequencing. Primer sequences are presented in Supplementary Table 1 online.
Cell culture
HS2 cells are HeLa cells stably expressing an SMN2-luciferase reporter gene. 14, 23 HeLa-705 cells stably express the human b-globin gene carrying the IVS2-705 mutation. 24 Conditions for cell culture, DNA transfections, lentiviral vector production in 293-T cells, titration on HeLa cells and transduction have been described. 8, 14 Modifications used here were that HS2 cells were kept under constant selection pressure with 500 mg ml À1 G418 (Invitrogen, Carlsbad, CA, USA) and that their media contained 10% tetracycline-free foetal calf serum (BioConcept, Allschwil, Switzerland). Doxycyline (Sigma, St Louis, MO, USA) was kept at À20 1C as a 2 mg ml À1 stock solution, freshly diluted at the time of the experiment and changed twice a week for experiments requiring long-term use of the drug.
For long-term culture and the shift experiments, HS2 cells were grown in 25 cm 2 tissue culture flasks. For the dose-response experiment, they were cultivated in sixwell plates. Induction/repression kinetics were measured in 5 cm petri dishes.
Fluorescence intensities were monitored by cytofluorometry (FACSCalibur, BD Biosciences Clontech, Palo Alto, CA, USA) and analysed with FlowJo 7.2.2 software (Tree Star Inc.). GFP and dsRed were monitored on the FL1 and FL3 channels, respectively, to limit fluorescence signal overlap. Compensation settings were generated by analysing HS2 cells singly transduced with pLV-T-U7 or pLV-tTR-KRAB-Red.
The copy numbers of integrated vectors were evaluated by real-time PCR as described.
14 For the pLV-tTR-KRAB-Red vector, the copy number was calculated as the difference in copy number compared to the parent cells singly transduced with the respective pLV-T-U7 vectors.
RNA analysis
RNA was extracted with homemade Tri-Reagent and resuspended in diethyl pyrocarbonate-treated water. This Tri-Reagent contained 800 mM guanidine thiocyanate, 400 mM ammonium thiocyanate, 100 mM sodium acetate (pH 5.0), 5% (v/v) glycerol and 38% (v/v) phenol saturated with 10 mM Tris, 1 mM EDTA (pH 8.0), and was supplemented with 0.1% (w/v) 8-hydroxy-chinoline as antioxidant and yellow colour indicator.
Reverse transcription of the SMN2-Luc mRNA was performed for 1 h at 37 1C in a total volume of 50 ml containing 3-5 mg total RNA, 10 pmol of SMN-Luc-Re primer, 50 U of Stratascript 6.0 reverse transcriptase (Stratagene, La Jolla, CA, USA), 500 mM of all four dNTPs (Roche, Indianapolis, IN, USA) and 8 U RNAsin (Promega, Madison, WI, USA). PCRs were carried out by using the FastStart PCR Master (Roche) in a volume of 25 ml with 5 ml of cDNA, 5 pmol each of the SMN-Luc-Fw (5 0 -FAM-labelled) and SMN-Luc-Re primers. Cycling conditions were 45 s at 95 1C, 1 min at 52 1C and 1 min at 72 1C for 28 cycles. The PCR product (1.2 ml) was mixed with 12 ml of GS500 LIZ standard (12.5 ml diluted Doxycycline-regulated antisense U7 snRNA J Marquis et al in 1 ml of 'Hi-Di' formamide; Applied Biosystems, Hercules, CA, USA) and run for fragment analysis on an ABI 3100 sequencer (Applied Biosystems). The relative amounts of the products lacking (296 bp) or containing (351 bp) SMN2 exon 7 were estimated from the areas of the corresponding peaks and the percentage of inclusion calculated as the proportion of the included compared with the total. This percentage of inclusion was invariant between 24 and 36 PCR cycles (data not shown).
For b-globin mRNA, reverse transcription was performed similarly, except that 100 pmol of (dT) 17 was used as primer. PCR was also performed as described above except that the primers were hBg-5 0 and hBg-3 0 . The (virtually complete) splicing correction was assessed qualitatively on ethidium bromide-stained agarose gels.
For primer extension, 10 pmol of U7 primer (Pex-U7-Universal) or U2 primer (Pex-U2-WT) was 5 0 -labelled with 10 U of T4 polynucleotide kinase (New England Biolabs, Ipswich, MA, USA) in the presence of 20 pmol of g-32 P-ATP and the labelled primers were used without further purification. Total RNA (5 mg) was slowly hybridized in a thermocycler with a mix of 300 fmol of both primers, and the reverse transcription reaction was performed as described above, except that the incubation was extended for 2 h. The products were separated on 15% denaturing polyacrylamide gels and the signals were analysed as described. 14 The level of the corrective U7 snRNA was expressed as a fraction of the U2 snRNA level. However, because of batch-to-batch variation in primer labelling, the level of U7 was further normalized to the maximum ratio (induced state) obtained for each run.
All primer sequences are presented in Supplementary  Table 1 online.
